# BTTC earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/BTTC) · [Earnings tab](https://www.lopjlb.com/stock/BTTC?tab=earnings) Updated: 2026-08-15T07:05:00 Quarters analyzed: 8 ## Cross-quarter narrative Across the earnings calls, Titan Pharmaceuticals' narrative shifted from commercialization efforts for Probuphine to a development-stage focus. Initially, the company faced challenges such as regulatory risks, operational bottlenecks, and funding dependencies. Despite these hurdles, Titan made progress in expanding its specialty pharmacy network, improving patient enrollment, and securing financing. However, the COVID-19 pandemic introduced new challenges, including disruptions to commercial activities, delays in clinical trials, and reimbursement issues. The company has since pivoted towards developing new programs like JT-09 and nalmefene, aiming for proof-of-concept data and IND filings. This strategic shift reflects Titan's adaptation to the evolving landscape and its efforts to address unmet medical needs. ## Latest CallCard · Q3 Titan Pharmaceuticals shifted back to a development-stage focus, highlighting JT-09 and nalmefene implant programs, a recent public offering, cost‑reduction restructuring, and aiming for proof‑of‑concept data in Q2 2021 and an IND filing in H1 2021. **Guidance:** maintained — Management reaffirmed existing timelines for JT‑09 proof‑of‑concept (Q2 2021) and nalmefene IND filing (first half of 2021). **Tone:** mgmt 0.6 · Q&A pressure 0 · divergence 0.5 Prepared remarks emphasize restructuring for growth, cost reductions and optimistic timelines for JT-09 proof‑of‑concept and nalmefene IND filing. ### Demand visibility Management noted large unmet need for chronic pruritus and opioid relapse treatments, but provided limited quantitative demand forecasts. Chronic pruritus affects an estimated 23‑44 million Americans and current therapies are ineffective; nalmefene implant targets opioid relapse post‑detoxification. ### Margins / costs Restructuring is expected to lower operating expenses. Our recent restructuring aims to position the company for future growth and is expected to result in substantial reductions in our fixed operating costs. ### Capital allocation Capital is being directed toward development of JT‑09 and nalmefene programs. We completed a public offering two weeks ago and are leveraging an $8.7 million NIDA grant to fund implant formulation, GMP manufacturing and non‑clinical studies. ### Milestones - **JT‑09 proof‑of‑concept** [on_track]: We expect to get this proof‑of‑concept data in the second quarter of 2021. - **Nalmefene IND filing** [on_track]: We remain on track to meet our next milestone, which is filing the IND in the first half of 2021. - **Public offering** [delivered]: Completed a public offering two weeks ago to fund ongoing programs. ### Fears / risks - **Capital raising**: Ability to raise capital may affect results. - **Regulatory approval**: Uncertainty around FDA approval pathways and required nonclinical data. - **Commercial wind‑down**: Winding down of U.S. commercial activities related to Probuphine. - **Intellectual property**: Potential patent and IP matters could impact development. - **Strategic agreements**: Reliance on strategic agreements and relationships introduces risk. ### Key quotes > “Our recent restructuring aims to position the company for future growth and is expected to result in substantial reductions in our fixed operating costs.” > “we remain on track to meet our next milestone, which is filing the IND in the first half of 2021.” > “We are now working towards establishing proof-of-concept of the JT-09 peptide, and we expect to get this proof-of-concept data in the second quarter of 2021.” > “Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital; the winding down of U.S. commercial activities related to” > “In September of 2019, the National Institute on Drug Abuse, or NIDA, awarded us approximately $8.7 million grant over 2 years for this program.” ## Quarter one-liners - **2020 Q3:** Titan Pharmaceuticals shifted back to a development-stage focus, highlighting JT-09 and nalmefene implant programs, a recent public offering, cost‑reduction restructuring, and aiming for proof‑of‑concept data in Q2 2021 and an IND filing in H1 2021. - **2020 Q2:** Titan Pharmaceuticals Q2 2020: Probuphine enrollments recovering to pre-COVID levels; new Indegene co-promotion and virtual REMS training launched; shareholder vote needed to increase authorized shares for capital raise; CEO Sunil Bhonsle plans retirement. - **2020 Q1:** Titan Pharmaceuticals reports modest Q1 sales growth but faces COVID‑19 disruptions, IND filing delay for nalmefene, and a postponed European launch while securing financing and expanding virtual training. - **2019 Q4:** Titan Pharmaceuticals reported Q4 2019 progress on Probuphine commercialization, expanded pharmacy networks and coverage, but missed its 500‑prescriber target and postponed post‑market studies amid COVID‑19 constraints. - **2019 Q3:** Titan Pharmaceuticals reports Q3 2019 results, highlighting Probuphine commercial progress (67% patient enrollment growth), NIDA grant extension for Nalmefene implant, and CBD feasibility study; cash $12.5M post-financing. - **2019 Q2:** Titan Pharmaceuticals Q2 2019: $0.5M revenue, $5.2M net loss; cash runway through Oct 2019 after $1.8M raise; Probuphine commercial progress with specialty pharmacy expansions, hub transition cutting delivery time to 2 weeks; EU approval (Sixmo) and Canada launch progressing; seeking capital for gro - **2019 Q1:** Titan Q1 2019: Probuphine commercial push with new specialty pharmacies (AllianceRx, Accredo) and AppianRx hub; EU Sixmo positive opinion; Phase 4 trials planned; $12.5M cash. - **2018 Q4:** Titan Pharmaceuticals reported progress on Probuphine commercialization, new European partnership, supply‑chain improvements, Phase 4 trial updates and modest Canadian royalty revenue, while noting regulatory and market uncertainties. ## Theme arcs - **Commercialization efforts** (deteriorating): Challenges in commercializing Probuphine due to regulatory and operational issues - **Development-stage focus** (new): Shift towards developing new programs like JT-09 and nalmefene - **COVID-19 impact** (deteriorating): Pandemic-related disruptions to commercial activities and clinical trials - **Financing and funding** (stable): Securing financing through public offerings and cost-reduction restructuring - **Regulatory risks** (stable): Ongoing regulatory challenges, but company is adapting to changing landscape ## Fear persistence - **Regulatory risk** [recurring]: Ongoing concerns about regulatory approvals and timelines - **Funding dependency** [recurring]: Company's reliance on funding to support development and commercial activities - **Commercial uptake** [recurring]: Challenges in driving adoption and sales of Probuphine - **COVID-19 impact** [recurring]: Pandemic-related disruptions to commercial activities and clinical trials - **Reimbursement challenges** [recurring]: Ongoing issues with reimbursement rates and processes ## Guidance path 2018 Q4:vague → 2019 Q1:vague → 2019 Q2:vague → 2019 Q3:vague → 2019 Q4:vague → 2020 Q1:maintained → 2020 Q2:vague → 2020 Q3:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/BTTC`